RFG Advisory’s Madrigal Pharmaceuticals MDGL Stock Holding History

RFG Advisory’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,000	Closed	-$428K	–	294
2018 Q3	$428K	Buy	+2,000	New	+$502K	0.11%	181

Other funds holding MDGL

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

RFG Advisory's MDGL Position: Q4 2018 in Review

RFG Advisory sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2018, closing a stake of 2,000 shares — an estimated $428K sold.

RFG Advisory first reported a position in MDGL in Q3 2018 and held it in 1 quarter. The position peaked at $428K in Q3 2018. 136 funds tracked by Wall St. Rank hold MDGL as of Q4 2018.

RFG Advisory reported no remaining Madrigal Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
RFG Advisory sold 2,000 Madrigal Pharmaceuticals shares in Q4 2018, an estimated $428K.
RFG Advisory first reported a position in Madrigal Pharmaceuticals in Q3 2018 and held it in 1 quarter.
RFG Advisory's Madrigal Pharmaceuticals position peaked at $428K in Q3 2018.
136 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2018.

Based on RFG Advisory's 13F filing for Q4 2018, filed 15 Feb 2019.